Biomunex Pharmaceuticals establishes US subsidiary
Biomunex Inc. to focus on R&D and business development activities in the US
Biomunex Pharmaceuticals, a biopharmaceutical company focused on providing immuno-therapeutics through the discovery and development of bi- and multi-specific antibodies, announces that it has established its US subsidiary, Biomunex Pharmaceuticals Inc., in Cambridge, Massachusetts, USA.
The opening of this subsidiary is a first step in the company’s strategy to expand Biomunex’ activities in the US, with initial focus on facilitating Research & Development partnerships and business development activities with pharmaceutical companies and leading academic institutions.
Most read news
Other news from the department business & finance

Get the chemical industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.